Details of the Drug
General Information of Drug (ID: DMD2NV7)
Drug Name |
Pindolol
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Betapindol; Blocklin; Calvisken; Carvisken; Decreten; Durapindol; Pectobloc; Pinbetol; Pindololum; Prindolol; Prinodolol; Pynastin; Visken; Blockin L; Blocklin L; LB 46; LB46; P 0778; Betapindol (TN); Blockin L (TN); Blocklin L (TN); Blocklin-L; Calvisken (TN); Cardilate (TN); Carvisken (TN); DL-LB 46; DL-Pindolol; Decreten (TN); Durapindol (TN); Glauco-Viskin; Glauco-visken; LB-46; P-6820; Pectobloc (TN); Pinbetol (TN); Pindololum [INN-Latin]; Prindolol (TN); Pynastin (TN); Visken (TN); Blocklin-L (TN); Glauco-Visken (TN); Pindolol (JP15/USP/INN); Pindolol [USAN:INN:BAN:JAN]; DL-4-[2-Hydroxy-3-(isopropylamino)propoxy]indole; (+-)-Pindolol; (1)-1-(1H-Indol-4-yloxy)-3-(isopropylamino)propan-2-ol; 1-((1-Methylethyl)amino)-3-(4-indolyloxy)-2-propanol; 1-(1H-Indol-4-yloxy)-3-((1-methylethyl)amino)-2-propanol; 1-(1H-Indol-4-yloxy)-3-(isopropylamino)-2-propanol; 1-(1H-Indol-4-yloxy)-3-[(1-methylethyl)amino]-2-propanol; 1-(1H-indol-4-yloxy)-3-(isopropylamino)propan-2-ol; 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)-propan-2-ol; 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol; 1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]propan-2-ol; 1-(1H-indol-4-yloxy)-3-[(propan-2-yl)amino]propan-2-ol; 1-(Indol-4-yloxy)-3-(isopropylamino)-2-propanol; 4-(2-Hydroxy-3-isopropylaminopropoxy)-indole; 4-(3-(Isopropylamino)-2-hydroxypropoxy)indole
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Therapeutic Class |
Antihypertensive Agents
|
|||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||
Structure | ||||||||||||||||||||
3D MOL | 2D MOL | |||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 248.32 | ||||||||||||||||||
Topological Polar Surface Area (xlogp) | 1.8 | |||||||||||||||||||
Rotatable Bond Count (rotbonds) | 6 | |||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 3 | |||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | |||||||||||||||||||
ADMET Property |
|
|||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Drug-Drug Interaction (DDI) Information of This Drug
Coadministration of a Drug Treating the Same Disease as Pindolol
Coadministration of a Drug Treating the Disease Different from Pindolol (Comorbidity)
|
Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug
References
1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 91). | ||||
---|---|---|---|---|---|
2 | Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy. CMAJ. 1997 Nov 1;157(9):1245-54. | ||||
3 | Health Canada Approved Drug Products: Apo-Pindolol (Pindolol) Oral Tablet | ||||
4 | BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs | ||||
5 | Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose | ||||
6 | Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds | ||||
7 | Dailymed: Pindolol Oral Tablet | ||||
8 | Are we misunderstanding beta-blockers. Int J Cardiol. 2007 Aug 9;120(1):10-27. | ||||
9 | Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8. | ||||
10 | Adrenergic activation of electrogenic K+ secretion in guinea pig distal colonic epithelium: involvement of beta1- and beta2-adrenergic receptors. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G269-77. | ||||
11 | Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock. Crit Care Med. 1999 Feb;27(2):325-31. | ||||
12 | Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6. | ||||
13 | Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging. 2006;23(12):977-95. | ||||
14 | Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404. | ||||
15 | beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):519-29. | ||||
16 | beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25. | ||||
17 | Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA "Nadolol in combination with indapamide and xipamide in resistant hypertensives." Eur J Clin Pharmacol 28 (1985): 29-33. [PMID: 3987783] | ||||
18 | Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167] | ||||
19 | Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ. | ||||
20 | Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028] | ||||
21 | Chapple DJ, Clark JS, Hughes R "Interaction between atracurium and drugs used in anaesthesia." Br J Anaesth 55 Suppl 1 (1983): s17-22. [PMID: 6688011] | ||||
22 | Canadian Pharmacists Association. | ||||
23 | Cerner Multum, Inc. "UK Summary of Product Characteristics.". | ||||
24 | Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL. | ||||
25 | Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA. | ||||
26 | Cerner Multum, Inc. "Australian Product Information.". | ||||
27 | Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA. | ||||
28 | Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
29 | Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ. | ||||
30 | Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
31 | Dufresne RL, Weber SS, Becker RE "Bupropion hydrochloride." Drug Intell Clin Pharm 18 (1984): 957-64. [PMID: 6439541] | ||||
32 | Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ. | ||||
33 | Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA. | ||||
34 | Chrysant SG "Experience with terazosin administered in combination with other antihypertensive agents." Am J Med 80 (1986): 55-61. [PMID: 2872808] | ||||
35 | Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
36 | Leor J, Levartowsky D, Sharon C, Farfel Z "Amiodarone and beta-adrenergic blockers: an interaction with metoprolol but not with atenolol." Am Heart J 16 (1988): 206-7. [PMID: 3394625] | ||||